Becton, Dickinson and Company $BDX Shares Sold by Securian Asset Management Inc.

Posted by Stanley Muller on May 12th, 2026

Securian Asset Management Inc. decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 43.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,793 shares of the medical instruments supplier’s stock after selling 5,986 shares during the period. Securian Asset Management Inc.’s holdings in Becton, Dickinson and Company were worth $1,512,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of BDX. Wellington Management Group LLP lifted its stake in Becton, Dickinson and Company by 9,056.3% during the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock worth $979,290,000 after acquiring an additional 5,174,944 shares in the last quarter. Vanguard Group Inc. lifted its stake in Becton, Dickinson and Company by 13.0% during the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock worth $7,118,282,000 after acquiring an additional 4,223,149 shares in the last quarter. First Eagle Investment Management LLC lifted its stake in Becton, Dickinson and Company by 13.8% during the 3rd quarter. First Eagle Investment Management LLC now owns 9,994,408 shares of the medical instruments supplier’s stock worth $1,870,653,000 after acquiring an additional 1,208,218 shares in the last quarter. Veritas Asset Management LLP lifted its stake in Becton, Dickinson and Company by 40.6% during the 3rd quarter. Veritas Asset Management LLP now owns 2,954,898 shares of the medical instruments supplier’s stock worth $553,068,000 after acquiring an additional 852,854 shares in the last quarter. Finally, Rakuten Investment Management Inc. acquired a new position in Becton, Dickinson and Company during the 3rd quarter worth about $152,931,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Activity

In related news, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the sale, the director directly owned 36,763 shares in the company, valued at $6,713,291.43. This represents a 2.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders sold 1,102 shares of company stock worth $198,909. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Trading Down 4.2%

NYSE:BDX opened at $143.11 on Tuesday. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. The stock has a market capitalization of $39.43 billion, a PE ratio of 36.23, a price-to-earnings-growth ratio of 10.60 and a beta of 0.22. The business’s 50-day simple moving average is $157.19 and its 200-day simple moving average is $180.46.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating the consensus estimate of $2.77 by $0.13. The firm had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Sell-side analysts expect that Becton, Dickinson and Company will post 12.59 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its Board of Directors has approved a share buyback plan on Tuesday, January 27th that permits the company to repurchase $10.00 million in shares. This repurchase authorization permits the medical instruments supplier to buy up to 0% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is 106.33%.

Analyst Ratings Changes

BDX has been the topic of several recent research reports. Argus cut their price target on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a report on Monday, March 23rd. The Goldman Sachs Group initiated coverage on Becton, Dickinson and Company in a report on Friday, April 10th. They set a “neutral” rating and a $167.00 price target on the stock. Evercore upped their price target on Becton, Dickinson and Company from $180.00 to $190.00 in a report on Thursday, May 7th. Citigroup cut their price target on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a report on Tuesday, February 10th. Finally, Royal Bank Of Canada set a $175.00 price target on Becton, Dickinson and Company in a report on Tuesday, April 14th. Seven analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $184.86.

Check Out Our Latest Stock Report on BDX

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.